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Case report 
type B, less papillary-endometrioid growth and more intra-
ductal components. The specimen of PDA results positive for 
prostate-specific antigen (PSA) and focally for mucin, con-
firming the prostatic epithelial origin of this tumour. PDA is 
detected in both the periurethral region and peripheral zone 
of the prostate and is considered high grade in the modified 
Gleason grading system. It is an aggressive tumour with a 
shortened average time to progression and worse prognosis 
compared with acinar adenocarcinoma (AA) (2).
Its clinical behaviour shows a number of differences in 
comparison with the well-known AA. Tumours displayed exo-
phytic growth into the prostatic urethra, with involvement 
of the verumontanum. The urethral orifices of the primary 
prostatic ducts can be uniformly involved. Obstructive symp-
toms or haematuria may develop at an early stage when the 
tumour is still small, and rectal examination is often normal 
or only suggestive of benign prostatic disease (3). The pro-
pensity of this tumour to spread within the urothelium makes 
local failure of common curative therapy (4).
Sometimes patients may present with secondary infertil-
ity and progressive decrease of ejaculatory volume and un-
usual metastases (testicle, penis and skin) were described in 
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Introduction
Ductal adenocarcinoma of the prostate (PDA) is a rare 
histological subtype, accounting for only 1-5% of all pros-
tate cancers (PCa). It was initially described by Melicow and 
 Pacher in 1967 (1).
Histologically, it is characterized by the presence of tall, 
pseudostratified columnar epithelium with abundant cyto-
plasm organized in a papillary or cribriform-papillary pattern. 
It can occur as a pure form or, more often, mixed with the 
typical adenocarcinoma pattern. With respect to histology, it 
has two growth patterns: type A, an exuberant papillary en-
dometrioid pattern with a focal intraductal component, and 
Clinical practice points
Ductal adenocarcinoma is a rare subtype of prostate cancer with a worse prognosis.
Histologically, it is characterized by the presence of tall, pseudostratified columnar epithelium with abundant cy-
toplasm organized in a papillary or cribriform-papillary pattern. Several clinical differences distinguish this subtype 
of prostate cancer by the conventional acinar adenocarcinoma: exophytic growth into the prostatic urethra, differ-
ent clinical presentation, different sites of metastasis and more aggressiveness. The rarity of this tumour forced to 
base our knowledge on small case series or on individual case reports, and does not help to establish appropriate 
guidelines. Therefore, the diagnosis of this tumour masks clinical implications that are still not well-understood.
We report the case of a 69-year-old Caucasian man with a diagnosis of pure prostate ductal adenocarcinoma that 
early developed multiple metastases after radical prostatectomy. The patient started hormonal therapy with a 
fast biochemical and radiologic (positron emission tomography–computed tomography, PET-CT) hormonal es-
cape. Therefore, we took the decision to perform chemotherapy with Taxotere along with prednisolone with a rel-
ative stability of prostate-specific antigen (PSA) level, but a new PET-CT scan showed a further progression of the 
disease. Finally, the patient underwent therapy with Abiraterone acetate that did not stop the cancer progression.
No therapeutic options available showed a good control of disease progression. PSA proved to be a poor marker 
while, on the contrary, PET-CT scan has proved to be particularly useful in the management of the disease pro-
gression. More efforts are required to add new knowledge about this tumour and assess what is known until now.
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patients with this subtype of tumour (5, 6). Finally, the rarity 
of this tumour forced to base our knowledge on small case 
series or on individual case reports and do not help to es-
tablish appropriate guidelines. In fact, some aspects of this 
cancer are still unclear and insufficient data are available re-
garding its response to conventional therapies especially af-
ter biochemical recurrence. Therefore, its management does 
not differ from that of the well-known AA, although the diag-
nosis of this tumour masks clinical implications that are not 
still well understood.
This report presents a description of clinical management 
and therapy response of a pure PDA case in a patient with 
malignancy recurrence after radical prostatectomy.
Discussion
A 69-year-old Caucasian man presented in our Depart-
ment in February 2011 with an elevated PSA value (6.3 ng/ml) 
and obstructive urinary symptoms in the form of increased 
urgency and nocturia. Informed consent for scientific divulga-
tion of data was obtained before all procedures. Digital rectal 
examination (DRE) was negative for prostate nodules. He did 
a 20 cores transrectal ultrasound-guided (TRUS) biopsy. This 
examination revealed a Gleason Score 8 (4 + 4) PDA in 10/20 
cores. The remaining 10/20 cores were cancer free. Initial 
bone scan and abdominal computed tomography (CT) were 
negative for metastatic disease. The radical prostatectomy 
and bilateral pelvic lymph node dissection (totally 11 L.Ns for 
right side and 8 L.Ns for left side) was performed.
Histopathology examination confirmed the presence of a 
pure Gleason score 8 (4 + 4) prostate confined PDA without 
nodal metastasis (pT2c N0 Mx Gleason 8 R0) (Fig. 1). Two 
months later, PSA value was 0.01 ng/ml, but it increases in 
the checks carried out 3, 6 and 8 months later (0.02, 0.29 and 
1.36 ng/ml, respectively) (Fig. 2). The patient underwent PET-
CT 11-choline to identify local or distant recurrences of the 
disease. The PET- CT scan identified two pulmonary nodules 
(approximately 1 cm) with a tracer uptake (apical segment of 
right lower lung lobe and anterior segment of left apical lung 
lobe) (Fig. 3A).
Therefore, we took the decision to perform CT-guided bi-
opsy of the lung nodules to assess a histological confirmation 
of distant recurrent PDA and to exclude a primitive lung tu-
mour (alveolar bronchiolar carcinomas can pick up choline). 
This examination confirmed the presence of metastatic PCa 
positive for PSA. Thus, the patient started hormonal therapy 
with LH-RH analogue (triptorelin pamoate 11.25) converted 
in major androgenic bloc (MAB) 6 months later (leuprolelin 
acetate 22.5 mg and bicalutamide 50 mg) for the partial re-
sponse of disease (PSA decreased to 0.02 ng/ml, but after 
3 months, it starts to arise again becoming 0.3 ng/ml in the 
following 6 months). Eight months later, no control of dis-
ease was obtained (PSA was still raising up 2 ng/ml) (Fig. 2). 
We took the decision to repeat a PET-CT scan (Fig. 3B) that 
showed an incongruity between the PSA level and the impor-
tant progression of disease (significant increase of all known 
lesions, onset of a new VIII left rib metastasis and develop-
ment of a new nodal mass with intense uptake of choline 
in left lung hilum). These findings preceded the slowly sub-
sequent increase of PSA value in the following 10 months. 
Therefore, when PSA became 7.34 ng/ml, we took the de-
cision to perform six cycles of chemotherapy with 3-weekly 
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Fig. 1 - Prostatic ductal adenocarci-
noma type (B) All figures are in ema-
toxylin and eosin stain (A-B-D) is in 
20× High-power field; (C) is at 10× 
High-power field). (a, B) and (D): The 
tumour shows the typical complex 
cribriform growth. (C): Comedone-
corsis.
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Fig. 2 - PSA value in relation to dif-
ferent treatment lines.
Fig. 3 - PET-CT progression of dis-
ease. (a) (after radical prostatec-
tomy): Metastases involve apical 
segment of right lower lung lobe 
and anterior segment of left api-
cal lung lobe. (B) (after hormonal 
therapy): Onset of a new VIII left 
rib metastases and development 
of a new nodal mass with intense 
capitation of choline in left lung 
hilum. (C) (after chemotherapy): 
Progression of all know previous 
findings aggravated by develop-
ment of multiple bilateral lung 
metastases.
Taxotere (Docetaxel®) 75 mg/m2 along with prednisolone 
5 mg twice-daily scheme. Close follow-up demonstrated a 
relative stability of the disease during chemotherapy based 
on PSA level (Fig. 2), but a new PET-CT was performed with 
evidence of a further progression of all known previous le-
sions aggravated by development of multiple (at least 10 new 
lesions) bilateral lung metastases (Fig. 3C). According with 
these findings, the decision was to switch chemotherapy to 
VII cycles of Abiraterone acetate (Zytiga®) 1000 mg daily ad-
ministration, but no significant response was observed and 
the PSA value increased until 27.98 ng/ml in the following 5 
months (Fig. 2). One month later, PSA raised up to 150 ng/ml. 
A new radiological valuation showed a further progression of 
metastatic disease and the patient died some weeks later.
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This case is emblematic of the variable and unpredictable 
behaviour of this rare histological type of PCa. The evidence 
of pulmonary metastases with an initial organ-confined pros-
tate cancer after prostatectomy (negative resection margins 
without evidence of lymph node and bone metastases) may 
suggest a different natural course of PDA. A review of the 
literature revealed that visceral (lung and liver) metastases 
were relatively common in PDA compared with usual pros-
tate AA (3). PDA may have the propensity to haematogenous 
spread rather than lymphatic in contrast to purely AA variant. 
In our opinion, this should be related to the histopathologi-
cal growth pattern and to the anatomic distribution of can-
cer within the gland. The development into glandular ducts, 
rather than inside the glandular berry, could facilitate direct 
vascular invasion instead of involvement of the glandular in-
terstice or of the periacinar lymphatic vessels.
Even though PDA cell produces PSA, the serum concen-
tration of this marker is not elevated in all patients. Morgan 
et al (7) stated that a number of patients with PDA should 
have PSA level less than 4.0 ng/ml at the diagnosis. There-
fore, PDA is less likely detectable based only on PSA serum 
level. On the basis of these evidences, the common tools 
used for the diagnosis, staging and follow-up of PCa may 
not have the same validity for this tumour subtype. Some 
Authors suggest adopting other alternative markers such as 
carcinoembryonic antigen (CEA); however, the small num-
ber of reported cases limits the significance of this obser-
vation (5). Considering the above reasons, we think that a 
contemporary and steady radiological examination should 
be useful to manage this tumour. PET-CT scan plays, in this 
experience, a role of particular importance in the disclosure 
of metastasis progression and its therapeutic management. 
Although the PSA serum values were in steady slight in-
crease, PET-CT scan showed a faster progression of the re-
curred disease (faster increase of volume and activity of me-
diastinal lesions and metastatic involvement on other sites). 
Thus, in our opinion, a radiological examination is necessary 
because it should help urologist to establish, with more 
precision, the appropriate timing for therapeutic decisions. 
Moreover, it is possible that the cancer had already given 
unrecognized lung metastases at primary tumour diagnosis. 
PET-CT scan (performed preoperatively) gives a reliable total 
body examination and could improve the diagnosis of me-
tastases not revealed using routinely tests recommended 
for PCa staging (i.e. abdomen CT and bone scan).
Finally, the PDA response to hormone therapy is still de-
batable showing controversial statements. Millar et al. found 
an excellent and long-term response (mean 5.4 years) to 
the endocrine control based on PSA level (8). In our experi-
ence, hormone therapy does not give an adequate control 
of disease. The PSA trend during hormonal therapy, in our 
case, might suggest the presence of a primitive castration-
resistant cancer or a fast hormonal escape conversion of the 
tumour (Fig. 2). Moreover, the PET-CT showed a rapid disease 
progression that was unexpected considering the PSA value 
alone.
In a case report, Aalok et al (9) underline, for the first 
time, as the chemotherapy (taxotere 75 mg along with pred-
nisone 5 mg daily scheme), quickly adopted after biochemi-
cal recurrence, assured the control of a PDA metastatic 
disease for more than 27 months (reduction of imaging 
findings and of the PSA level). Unfortunately, no other data 
are available to compare these results. In our experience, 
the same chemotherapy scheme showed only a 5 months 
partial control of PSA level (ranged from 7.5 to 9.5 ng/ml) 
not confirmed by PET-CT findings (progression of all known 
previous findings aggravated by development of multiple bi-
lateral lung metastases).
Edgar Linden-Castro et al. (10), for the first time, observed 
that a patient treated with Abiraterone acetate 1000 mg 
had a PSA progression time of 9 months and radiographic 
progression-free survival of 11 months. In our experience, 
Abiraterone acetate did not stop the progression of the PSA, 
which recorded a new peak of increase up to 27 ng/ml. Un-
fortunately, a new radiological evidence is not still available, 
but we can expect a new important disease progression.
Summarizing, in our experience, the available therapies 
used for metastatic PCa treatment seem to slow down but not 
to stop the disease progression of PDA with a survival after 
recurrence of about 45 months (significantly less if compared 
with a Gl 8 typical AA). Probably, some histological charac-
teristics (pure or mixed, growth pattern Type A or Type B) or 
other still unknown factors may affect the tumour response 
to therapy and explain the differences between our findings 
and those of other cases. So, more efforts are required to add 
new knowledge about the biology of this tumour and assess 
what is known until now.
Conclusion
Our findings confirm that PDA is a more aggressive variant 
of PCa. PSA may be an insufficient marker for disease man-
agement and a partial or complete PSA response to therapy 
does not necessarily mean lack of disease progression. New 
markers or radiological evaluation should be applied to im-
prove the management of this aggressive variant and, in our 
experience, PET -CT scan has proved to be particularly useful. 
We observed that the available cures seem to slow down but 
not stop the disease progression. Probably, some histological 
characteristics or other still unknown factors may affect the 
tumour response to therapy. More efforts are required to add 
new knowledge about the biology of this tumour and assess 
what is known until now.
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